September 4, 2012
The International Center for Dispute Resolution has ruled that India's Glenmark Pharmaceuticals has the right to sell Crofelemer, its drug for HIV-associated diarrhea, in 140 countries. The medication was developed by Glenmark with U.S.-based partners Napo Pharmaceuticals and Salix Pharmaceuticals Ltd. Glenmark sought arbitration in the United States in December, after Napo terminated a three-party agreement that gave Glenmark exclusive distribution rights for Crofelemer in India and 139 other nations. In a statement, Glenmark said the ICDR found that Napo breached the agreement by revealing confidential information about manufacturing Crofelemer to Aptuit Laurus, another drugmaker. Glenn Saldanha, Glenmark's chair, said the ruling will permit the company "to further its commitment to working with relief agencies to distribute Crofelemer to affected populations."
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.